ALKS stock news

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA (NASDAQ: SNY ). Here are the key catalysts that can sway biotech stocks in the unfolding week. Conferences SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts Canaccord Genuity Growth Conference - Aug. 7-8, in Boston Clinical Trial Readouts Leap Therapeutics Inc (NASDAQ: LPTX ) is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. (NYSE: MRK )'s Keytruda in ornithine transcarbamylase deficiency. Pending Mid-2019 Clinical Readouts Immunic Inc (NASDAQ: IMUX ) – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis Alkermes Plc (NASDAQ: ALKS ) – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis IMMUTEP LTD/S ADR (NASDAQ: IMMP ) – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer Aevi Genomic Medicine Inc (NASDAQ: GNMX ) – Phase 1b data for AEVI-002 in pediatric … Read more
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting forecast-beating earnings. Intec Pharma Ltd (NASDAQ: NTEC ) and Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) lost much of their market value this week on clinical trial setbacks. The following are some of the key biotech catalysts in the upcoming week: Conferences 2nd Annual Biotechnology Congress: July 29-30 in Chicago. 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden. 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago. Clinical Trial Readouts (mid-2019 releases) Immunic Inc (NASDAQ: IMUX ): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis. Conatus Pharmaceuticals Inc (NASDAQ: CNAT ): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis. Read more
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: … Read more
Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia. Read more
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 30) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Advaxis, Inc. (NASDAQ: ADXS ) Alkermes Plc (NASDAQ: ALKS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Mylan NV (NASDAQ: MYL ) Myovant Sciences Ltd (NYSE: MYOV )(announced $100 million worth of common stock offering) Neuronetics Inc (NASDAQ: STIM ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teligent Inc (NASDAQ: TLGT ) Urogen Pharma Ltd (NASDAQ: URGN ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Zafgen Inc (NASDAQ: ZFGN ) ( reacted to safety concerns over its diabetes drug following the Type A meeting with FDA) Stock In Focus Merrimack Board Decides Against Sale Following Strategic Review Following the completion of a strategic review, Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) said its board has decided to restructure the company such that its … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity … Read more
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more

Proudly made at

ROCKIT